AMERICAN ASSOCIATION FOR CANCER RESEARCH  
86th Annual Meeting

Donald S. Coffey, Program Chairperson  
Metro Toronto Convention Centre, Toronto, Ontario, Canada  
March 18-22, 1995

Titles of Major Sessions  
(Confirmed Chairpersons in Parentheses)

PLENARY SESSION  
An Integrated View of the Cancer Cell (Donald S. Coffey)

SYMPOSIA  
The Cell Cycle and Tumor Suppressor Genes (Thea D. Tisty)  
DNA Damage and Repair (Philip C. Hanawalt)  
Natural Products in Chemoprevention of Cancer (Michael B. Sporn)  
Ribozymes and Antisense Oligonucleotides and the Alteration of Gene Expression (Kevin J. Scanlon)  
Genetic Susceptibility to Cancer (Kenneth W. Kinzler)  
Contributions of Environmental Factors to Cancer (Kenneth Olden)  
Cell Surface Glycosylation Defining Malignancy (Sen-rieho Hakomori)  
Peripheral Stem Cells and High-Dose Chemotherapy (Peter J. Quesenberry)  
Apoptosis (Alan R. Eastman)  
Biology of Radiation Oncology (H. Rodney Withers and C. Norman Coleman)  
Biomarkers of Carcinogenesis (David Sidransky)  
Transcription Factors and Carcinogenesis (Frank J. Rauscher III)  
Gene Therapy in Cancer Clinical Trials  
Telomerases and Telomeres (Carol W. Greider and Jerry W. Shay)  
Extracellular Matrix, Gene Expression, and Cell Signalling (Hynda K. Kleiman)  
Mechanistic Basis for Ethnic Differences in Cancer Risk (Kenneth Olden)  
Signal Transduction and Gene Control and Development (James E. Darnell)  
Angiogenesis (Judah Folkman and Adrian L. Harris)  
Genes, Development, and Cancer (Eric N. Olson)  
Growth Factors, Receptors, and Differentiation (Angie Rizzino)  
New Strategies and Targets for Chemotherapy (Joseph R. Bertino and Eddie Reed)  
Genetic Approaches to Invasion and Metastasis (Robert S. Kerbel and Patricia S. Steeg)  
Immunotherapy: Tumor Vaccines (David A. Berd)  
Graft versus Tumor Effects (Richard J. O'Reilly)  
Dietary Intervention in Hormonal Carcinogenesis (Diane F. Birt and Lovell A. Jones)  
The Role of Stromal-Epithelial Interactions in Growth and Neoplasia (Leland W. K. Chung)  
Cancer Prevention and Intermediate Biomarkers (Peter Greenwald)  
Combinatorial Chemistry for Anticancer Drug Discovery (Sydney E. Salmon)  
Translational Research in Breast Cancer (Marc E. Lippman)  
DNA Methylation (Peter A. Jones and Stephen B. Baylin)

METHODS WORKSHOPS  
General, In Situ, and Quantitative PCR (including Differential Display) (Saraswati Sukumar)  
Gene Targeting (Janet Rossant and Andras Nagy)

CONTROVERSY SESSIONS  
Are Estrogens Implicated in Breast Cancer? (Lovel A. Jones)  
Is Mammography Before Age 50 Beneficial? (Virginia L. Ernser)  
What Are the Limits and Benefits of PSA as a Screening Tool? (John Trachtenberg)  
Breast Cancer Prevention: What Will We Advise Women with BRCA1? (Louise C. Strong)  
What Are the Risks of Electromagnetic Fields in Causing Cancer? (Mark A. Israel)  
Is Bone Marrow Transplantation Indicated for Breast Cancer? (Nancy E. Davidson)

MEET-THE-EXPERT SUNRISE SESSIONS  
New Developments in Clinical Pharmacology (Merrill J. Egorin)

Site-specific Gene Expression in Transgenic Animals (Norman Greenberg)  
Organ-specific Carcinogenesis (Cheryl Lyn Walker)  
Modeling and Analyzing Clinical Trials (Steven Pantadosi)  
Multivariate Determinants of Radiocurability (Richard P. Hill)  
Multidrug Resistance (Victor Ling)  
Cytokines, Vaccines, and Gene Therapy (Jonathan W. Simons)

Tyrosine Kinases and Phosphatases  
Prostate Cancer (John T. Isaacs)  
Lung Cancer (Stephen B. Baylin)  
Colon Cancer (Ronald N. Buick)  
Pediatric Malignancies (Joseph V. Simone)  
Hematological Malignancies (Lee M. Nadler)  
Stem Cell Transplantation (Elizabeth J. Shpall)  
Molecular Determinants of Multidrug Resistance (Elizabeth W. Newcomb)

Is a Mutagenic Event Involved in Initiation? (Ann R. Kennedy)  
Glutathione S-Transferase (Kenneth D. Tew)  
Farnesyl Transferase as a Target for Therapy (Alexander W. Wood)  
Liver Cancer Etiology and Prevention (John D. Groopman)  
Biochemical Determinants of Carcinogenesis (Allan B. Okey)

EDUCATIONAL WORKSHOPS  
To Be Announced

Further Information:  AACR Office • Public Ledger Building • Suite 816 • 150 S. Independence Mall West  
Philadelphia, PA 19106-3483 • TELEPHONE (215) 440-9300 • FAX (215) 440-9313
AMERICAN ASSOCIATION FOR CANCER RESEARCH

GERTRUDE ELION CANCER RESEARCH AWARD

Supported by an Educational Grant from
Wellcome Oncology
Burroughs Wellcome Co.

- This Award was established in honor of Nobel Laureate Dr. Gertrude Elion, Scientist Emeritus at the Burroughs Wellcome Co. and Past President and Honorary Member of the AACR.

- The Gertrude Elion Cancer Research Award is a one-year, $30,000 grant for a scientist in the U.S. or Canada engaged in meritorious basic, clinical, or translational research in cancer etiology, diagnosis, treatment, or prevention at the level of Assistant Professor.

- The AACR will reimburse the Awardee for travel to the Annual Meeting where Dr. Elion will personally present this Award.

Eligibility
Candidates must have completed postdoctoral studies or clinical fellowships not later than July 1 of the Award year, and ordinarily not more than five years earlier. Tenured faculty in academia, government employees, and employees of private industry are not eligible for this award. A Candidate need not be a member of the AACR at the time of application, but must be nominated by a Member of the AACR. Associate Members may not be nominators.

Selection Process
Applications are evaluated by a Committee consisting of AACR Members who are experts in basic, clinical, and translational cancer research. Complete applications must be submitted by January 10, 1995 to be considered for the 1995 Award.

For Further Information/Application Forms
AMERICAN ASSOCIATION FOR CANCER RESEARCH
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
Telephone: (215) 440-9300
FAX: (215) 440-9313
ATTN.: Jenny Anne Horst-Martz
AMERICAN ASSOCIATION FOR CANCER RESEARCH

The American Association for Cancer Research (AACR) is a professional society of over 10,000 scientists and physicians involved in cancer research. Members in the AACR enjoy

• subscriptions to the journals Cancer Research, Cell Growth & Differentiation (CG&D), Cancer Epidemiology, Biomarkers & Prevention, and (starting in 1995) Clinical Cancer Research at reduced member rates

• early notification of and reduced registration rates at the AACR Annual Meeting and Special Conferences

• Employment Register, Directory of Members, public education activities, and many other benefits

Special programs to provide enhanced career development opportunities for minority scientists include

• Mentorship Program

• Travel Awards to Scientific Meetings

American Association for Cancer Research
Public Ledger Building, Suite 816
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Telephone: (215) 440-9300
FAX: (215) 440-9313

EMPLOYMENT REGISTER OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR)

An Important Listing of Available Positions and Candidates in All Disciplines of Cancer Research

• Publication of Position and Candidate Advertisements in Cancer Research and the Proceedings of the American Association for Cancer Research

• Arrangement of Interviews at the AACR Annual Meeting in Toronto, Ontario, Canada (March 19-22, 1995)

• For forms and information:
  Employment Register
  American Association for Cancer Research
  Public Ledger Building, Suite 816
  150 S. Independence Mall West
  Philadelphia, PA 19106-3483
  Telephone: (215) 440-9300
  FAX: (215) 440-9313

Section of Urology
The University of Michigan Medical Center

THE DEPARTMENT OF SURGERY seeks M.D. and Ph.D. candidates for faculty positions in the Section of Urology. Candidates should have demonstrated research experience, ability to obtain grant funding, and interest in an academic career. Academic rank will be determined by applicant's credentials. Please send curriculum vitae to: Joseph Oesterling, M.D., Professor and Head of Urology, Department of Surgery, THE UNIVERSITY OF MICHIGAN MEDICAL CENTER, 2916 Taubman Health Care Center, Ann Arbor, MI 48109-0330.

The University of Michigan is a Non-Discriminatory/Affirmative Action Employer and strongly encourages minorities and females to apply.

The University of Michigan
AACR SPECIAL CONFERENCE IN CANCER RESEARCH

Translational Research in Cancer:
New Opportunities for Progress

Supported by a Generous Grant from the
National Institute of Environmental Health Sciences

November 29 - December 4, 1994
The Grove Park Inn, Asheville, North Carolina

CONFERENCE CHAIRPERSON
Carlo M. Croce / Philadelphia, PA

PROGRAM COMMITTEE

Martin D. Abeloff / Baltimore, MD
Clara D. Bloomfield / Buffalo, NY
Bruce D. Cheson / Bethesda, MD

Robert L. Comis / Philadelphia, PA
Mark A. Israel / San Francisco, CA
Marc E. Lippman / Washington, DC

SCIENTIFIC PROGRAM

Keynote Address
Webster K. Cavenee / La Jolla, CA

Hematopoietic Malignancies - Biology
Max D. Cooper / Birmingham, AL
Edward A. Clark / Seattle, WA
Bice Perussia / Philadelphia, PA
Drew M. Pardoll / Baltimore, MD

Hematopoietic Malignancies - Molecular Biology
Carlo M. Croce / Philadelphia, PA
Ell Canani / Rehovot, Israel
Stephan W. Morris / Memphis, TN

Hematopoietic Malignancies - Treatment
Albert B. Deisseroth / Houston, TX
Neal A. Flomenberg / Milwaukee, WI
Lee M. Nadler / Boston, MA
Bruce D. Cheson / Bethesda, MD
John C. Reed / La Jolla, CA
Clara D. Bloomfield / Buffalo, NY

Cytogenetics of Solid Malignancies/
Sarcomas/Brain Tumors
Felix Mittelman / Lund, Sweden
Frederic G. Barr / Philadelphia, PA
Mark A. Israel / San Francisco, CA
Mark Noble / London, England

Prostate Cancer and Ovarian Cancer
John T. Isaacs / Baltimore, MD
Donald S. Coffey / Baltimore, MD
Thomas C. Hamilton / Philadelphia, PA
Robert F. Ozols / Philadelphia, PA

Lung Cancer
John D. Minna / Dallas, TX
Susan L. Naylor / San Antonio, TX
Paul A. Bunn, Jr. / Denver, CO

Breast Cancer
Marc E. Lippman / Washington, DC
Ira Pastan / Bethesda, MD
Karl Erik Hellström / Seattle, WA
Charles R. King / Gaithersburg, MD
Lance A. Liotta / Bethesda, MD
Jackson B. Gibbs / West Point, PA
Martin D. Abeloff / Baltimore, MD

Colorectal Cancer
Reymond L. White / Salt Lake City, UT
Richard Fishel / Burlington, VT
Glenn Steele, Jr. / Boston, MA

Applicants are encouraged to submit abstracts for poster presentation.

Information and Application Forms
American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)
Cover Legend

Urinary bladder carcinogenesis has become a fruitful area of investigation (see Cancer Research cover, Vol. 47, February 15, 1987, honoring Drs. G. Bonser and L. Pyrah and their colleagues at the Leeds University Medical School) because of the several identifiable etiological factors involved in the human disease and availability of animal models closely resembling it. Samuel M. Cohen and Ryoichi (Bob) Oyasu, both surgical pathologists, have contributed significantly to our understanding of biological and clinical aspects of bladder cancer in humans by developing and studying appropriate rodent models.

In 1967, Dr. Cohen, with James Price and George T. Bryan at the University of Wisconsin, described the carcinogenicity of 2,3-diaminopyridine (2,3-DAP) and 2-acetylaminofluorene (AASF) in the rat, providing a model for studying the effects of these compounds on bladder cancer development. They showed that 2,3-DAP and AASF are potent bladder carcinogens, with AASF being the more potent of the two. These studies have helped to identify the importance of metabolic activation of bladder carcinogens and the role of nitroso compounds in bladder cancer initiation.

In 1979, Dr. Oyasu and his colleagues at the University of Wisconsin developed the first mouse model of bladder cancer, using the 2-acetylaminofluorene (AASF) carcinogen. They showed that AASF was a potent bladder carcinogen, with the highest incidence of bladder tumors occurring in the papillary and muscularis layers of the bladder. This model has been used extensively to study the mechanisms of bladder cancer development and to test new chemotherapy agents.

In conclusion, Dr. Cohen and Dr. Oyasu have made significant contributions to our understanding of bladder cancer, and their work has helped to advance the field of bladder cancer research.